Clinical Trial Detail

NCT ID NCT03916627
Title Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications

hepatocellular carcinoma

head and neck squamous cell carcinoma

lung non-small cell carcinoma

Therapies

Cemiplimab

Age Groups: adult senior

No variant requirements are available.